Login to Your Account

Cardiome Raising $84M Publicly To Boost AF Drug Development

By Jennifer Boggs

Friday, January 19, 2007
A month after its partner resubmitted a new drug application for arrhythmia drug vernakalant, Cardiome Pharma Corp. is adding $84 million to its coffers through a public offering to support further work on vernakalant, including the development of an oral formulation of the drug. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription